Synergy between leptin therapy and a seemingly negligible amount of voluntary wheel running prevents progression of dietary obesity in leptin-resistant rats.
OBJECTIVE
We examined whether chronic leptin treatment of diet-induced obese rats promotes or alleviates the susceptibility to continued high-fat feeding. Second, we examined if voluntary wheel running is beneficial in reducing the trajectory of weight gain in high-fat-raised leptin-resistant rats.


METHODS
Sprague-Dawley rats were fed a standard diet or a high-fat diet for 5 months, and then hypothalamic leptin overexpression was induced through central administration of adeno-associated virus-encoding leptin while continuing either the standard or high-fat diet. Two weeks later, half of the rats in each group were provided access to running wheels for 38 days while being maintained on either a standard or high-fat diet. RESULTS; In standard diet-raised rats, either wheel running or leptin reduced the trajectory of weight gain, and the combined effect of both treatments was additive. In high-fat-raised leptin-resistant rats, leptin overexpression first transiently reduced weight gain but then accelerated the weight gain twofold over controls. Wheel running in high-fat-raised rats was sixfold less than in standard diet-raised rats and did not affect weight gain. Surprisingly, wheel running plus leptin completely prevented weight gain. This synergy was associated with enhanced hypothalamic signal transducer and activator of transcription (STAT) 3 phosphorylation and suppressor of cytokine signaling 3 expression in wheel running plus leptin compared with leptin-treated sedentary high-fat counterparts. This enhanced STAT3 signaling associated with the combination treatment occurred only in high-fat-raised, leptin-resistant rats and not in standard diet-raised, leptin-responsive rats.


CONCLUSIONS
Chronic leptin treatment in diet-induced obese rats accelerates dietary obesity. However, leptin combined with wheel running prevents further dietary weight gain. Thus, this combination therapy may be a viable antiobesity treatment.
Shapiro
Alexandra
A
Department of Pharmacology and Therapeutics, Box 100267, University of Florida College of Medicine, Gainesville, Florida 32610, USA.
Matheny
Michael
M
Zhang
Yi
Y
Tümer
Nihal
N
Cheng
Kit-Yan
KY
Rogrigues
Enda
E
Zolotukhin
Sergei
S
Scarpace
Philip J
PJ
D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1 / Q000032:analysis; D000273:Adipose Tissue / Q000737:chemistry; D000818:Animals; D003345:Corticosterone / Q000097:blood; D004032:Diet; D004435:Eating; D005786:Gene Expression Regulation; D015316:Genetic Therapy; D020738:Leptin / Q000235:genetics* / Q000378:metabolism*; D008297:Male; D009043:Motor Activity / Q000502:physiology*; D009765:Obesity / Q000628:therapy*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
D020738:Leptin; D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1; D003345:Corticosterone